Information

全研究実績

2023

基礎
367

Komori T, Kuwahara T, Fujimoto T, Sakurai M, Koyama-Honda I, Fukuda M, Iwatsubo T: Phosphorylation of Rab29 at Ser185 regulates its localization and role in the lysosomal stress response in concert with LRRK2 J Cell Sci 136:jcs261003, 2023

基礎
368

Cho H-J, Min J-W, Byeong-Gyu Park B-G, Kim SH, Im J-Y, Kim DH, Lee J-Y, Yoon SJ, Kang H, Iwatsubo T, Ryu J-H: The microRNA-485-3p concentration in salivary exosome-enriched extracellular vesicles is related to amyloid beta deposition in the brain of patients with Alzheimer’s disease. Clinical Biochemistry 118:110603, 2023

基礎
365

Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Burkett P, Chen T, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A, Budd Haeberlein S: Investigating partially discordant results in phase 3 studies of aducanumab. J Prev Alzheimers Dis 10: 171-177, 2023

基礎
371

Sano T, Ochiai T, Nagayama T, Nakamura A, Kubota N, Kadowaki T, Wakabayashi T, Iwatsubo T: Reduced insulin signaling mitigates Alzheimer amyloid-β pathology by promoting expression of extracellular matrix proteins in the brain. J Neurosci 43:7226-7241, 2023

基礎
370

Watanabe H, Murakami R, Tsumagari K, Morimoto S, Hashimoto T, Imaizumi K, Sonn I, Yamada K, Saito Y, Murayama S, Iwatsubo T, Okano H: Astrocytic APOE4 genotype-mediated synapse degeneration in human pluripotent stem cell model. Stem Cell Rep 18:1854-1869, 2023

基礎
364

Kasuga K, Tsukie T, Kikuchi M, Tokutake T, Washiyama K, Shimizu S, Yoshizawa H, Kuroha Y, ajima R, Mori H, Arakawa Y, Onda K, Miyashita A, Onodera O, Iwatsubo T, Ikeuchi T: The clinical application of optimized AT(N) classification in Alzheimer’s clinical syndrome (ACS) and non-ACS conditions. Neurobiol Aging 127:23-32, 2023

基礎
369

Sperling RA, Donohue MC, Raman R, Rafii M, Johnson K, Masters C, Van Dyck C, Iwatsubo T, Marshall G, Yaari R, Mancini M, Holdridge KC, Case M, Sims J, Aisen PS: Trial of Solanezumab in preclinical Alzheimer’s disease. N Engl J Med 389:1096-1107, 2023

基礎
366

Ellison TS, Cappa SF, Garrett D, Georges J, Iwatsubo T, Kramer JH, Lehmann M, Lyketsos C, Maier AB, Merrilees J, Morris JC, Naismith SL, Nobili F, Pahor M, Pond D, Robinson L, Soysal P, Vandenbulcke M, Weber CJ, Visser PJ, Weiner M, Frisoni GB: Outcome measures for Alzheimer’s disease: a global inter-societal Delphi consensus. Alzheimer Dement 19:2707-2729, 2023

基礎
363

van Dyck CH, Swanson CJ, Aisen P, Bateman R, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T: Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9-21, 20232

PATE TOP